


1/17

FIG. 1



2/17

FIG. 2

Every 1 wk	0.75mg/kg	1.0mg/kg	1.25mg/kg	1.5mg/kg	1.67 mg/kg
Relative AUC to 2.5mg/kg Q3wks	0.9x	1.2x	1.5x	1.8x	2x
Total dose Q3wks	2.25mg/kg	3mg/kg	3.75mg/kg	4.5mg/kg	5mg/kg

D1 & D8 every 3 wks	1.25 mg/kg	1.5 mg/kg	1.75 mg/kg	2.0 mg/kg	2.25 mg/kg	2.5 mg/kg
Relative AUC to 2.5mg/kg Q 3wks	1x	1.2x	1.4x	1.6x	1.8x	2x
Total dose Q3wks	2.5 mg/kg	3 mg/kg	3.5 mg/kg	4 mg/kg	4.5 mg/kg	5 mg/kg

3/17

FIG. 3A




FIG. 3B





FIG. 3C



4/17

FIG. 4A




FIG. 4B




FIG. 4C





FIG. 4D



----- 1.5 mg/kg D1, 8 q3wk
—— 1.0 mg/kg q1wk

5/17

FIG. 4E




FIG. 4F




FIG. 4G





FIG. 4H



----- 1.5 mg/kg D1, 8 q3wk
—— 1.0 mg/kg q1wk

6/17

FIG. 4I

	IV 1.0mg/kg Q1wk		IV 1.5mg/kg D1,8 Q3wk	
	AUC _{0-21day} (nM*day)	Ctrough (nM)	AUC _{0-21day} (nM*day)	Ctrough (nM)
ADC w/ DAR ≥ 4	383	2.37	383	0.13
ADC w/ DAR 2-3	963	23.8	964	12.2
ADC w/ DAR 1	678	24.2	679	13.9
ADC w/ DAR 0	906	33.9	908	19.1
Total antibody	3072	84.8	3074	43.5
ADC	1751	41.2	1751	20.3
Antibody- conjugated MMAE	4489	80.1	4490	36.6
MMAE	110	4.20	110	1.87

7/17

FIG. 5A




FIG. 5B





FIG. 5C



BV and LV 1 mg/kg q1wk
Assume average DAR = 1 after day 7

8/17

FIG. 5D





FIG. 5E



BV and LV 1 mg/kg q1wk
Assume average DAR = 1 after day 7

FIG. 6A
9/17
ADC C_{trough} vs BCR




FIG. 6B
ADC C_{max} vs BCR





FIG. 6C
Free MMAE vs BCR




10/17

FIG. 7A

	Standardized Dose Level (mg/kg/wk)							
	0.4	0.45	0.6	0.75	0.9	1.05	1.2	Total
BV Study 35-01 Q3W								
n	3	0	12	0	11	0	1	27
PN	0		50%		64%		0	48%
Gr $\geq$ 2 PN	0		17%		27%		0	19%
Neutropenia	0		42%		45%		0	37%
BV Study 35-02 Q1W								
n	0	3	5	11	12	6	0	37
PN		33%	80%	73%	75%	83%		73%
Gr $\geq$ 2 PN		0	40%	27%	33%	67%		35%
Neutropenia		33%	0	18%	17%	17%		16%

11/17

FIG. 7B



CPH Regression	HR	95% CI	P-value
Q1week vs. Q3weeks	1.29	(0.49, 3.40)	0.61

12/17

FIG. 8A





FIG. 8B



13/17

FIG. 8C

Simulation Scenarios	Dose (mg / kg)	Dosing Schedule	Dose Intensity (mg / kg / wk)	C _{max,ss} / C _{trough,ss} , c2		AUC _{tau} , c2	
				ADC (ug/mL)	MMAE (ng/mL)	ADC (ug*day/mL)	MMAE (ng*day / mL)
1	2.5	D1 Q3wk	0.83	78.1/1.75	7.69/0.46	208	67.9
2	0.75	QW	0.75	27.1/4.18	4.23/2.3	184	71
3	1.0	D1,8,15 Q4wk	0.75	35.7/2.43	5.41 / 0.91	253	92.4
4	1.25	D1,8 Q3wk	0.83	43.4/2.61	6.06/1.02	207	73.9

14/17

FIG. 9A





FIG. 9B



15/17

FIG. 9C

Simulation Scenarios	Dose (mg / kg)	Dosing Schedule	Total Dose per 3-week cycle (mg/kg)	C _{max} _{CS}		AUC _{CS 21d,CS}	
				ADC (ug/mL)	MMAE (ng/mL)	ADC (ug*day / mL)	MMAE (ng*day/mL)
1	2.5	Q3wk	2.5	78.5	7.80	215	69.3
2	1.0	D1, 8 Q3wk	2.0	35	4.95	171	60.9
3	1.25	D1, 8 Q3wk	2.5	43.7	6.19	214	76.2
4	1.5	D1, 8 Q3wk	3.0	52.5	7.43	257	91.4
5	1.75	D1, 8 Q3wk	3.5	61.2	8.67	299	107

16/17

FIG. 10A

ADC: 1.0 and 1.25 mg/kg Q1w vs. 2.5 mg/kg Q3w




FIG. 10B

MMAE: 1.0 and 1.25 mg/kg Q1w vs. 2.5 mg/kg Q3w




FIG. 11

